Maze Therapeutics, Inc. (NASDAQ:MAZE – Get Free Report) CMO Harold Bernstein sold 9,705 shares of Maze Therapeutics stock in a transaction on Friday, September 4th. The shares were sold at an average price of $26.22, for a total transaction of $254,465.10. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Harold Bernstein also recently made the following trade(s):
- On Thursday, September 3rd, Harold Bernstein sold 5,189 shares of Maze Therapeutics stock. The stock was sold at an average price of $26.01, for a total transaction of $134,965.89.
- On Wednesday, September 2nd, Harold Bernstein sold 5,106 shares of Maze Therapeutics stock. The shares were sold at an average price of $26.47, for a total value of $135,155.82.
- On Tuesday, September 1st, Harold Bernstein sold 16,141 shares of Maze Therapeutics stock. The stock was sold at an average price of $26.36, for a total value of $425,476.76.
- On Thursday, August 13th, Harold Bernstein sold 16,142 shares of Maze Therapeutics stock. The stock was sold at an average price of $27.61, for a total value of $445,680.62.
- On Wednesday, July 1st, Harold Bernstein sold 14,609 shares of Maze Therapeutics stock. The shares were sold at an average price of $29.90, for a total value of $436,809.10.
Maze Therapeutics Stock Up 1.0%
Maze Therapeutics stock opened at $24.82 on Friday. The stock has a market capitalization of $1.38 billion, a PE ratio of -9.85 and a beta of 2.17. Maze Therapeutics, Inc. has a 12 month low of $20.00 and a 12 month high of $53.65. The business has a 50 day simple moving average of $28.33 and a 200-day simple moving average of $30.50. The company has a debt-to-equity ratio of 0.09, a current ratio of 18.31 and a quick ratio of 18.31.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently modified their holdings of the company. Frazier Life Sciences Management L.P. grew its holdings in shares of Maze Therapeutics by 10.2% in the second quarter. Frazier Life Sciences Management L.P. now owns 5,032,915 shares of the company’s stock valued at $150,182,000 after purchasing an additional 465,641 shares during the period. TRV GP IV LLC acquired a new stake in Maze Therapeutics during the second quarter worth about $133,502,907. ARCH Venture Management LLC purchased a new position in Maze Therapeutics during the second quarter worth about $122,983,582. BlackRock Inc. acquired a new position in Maze Therapeutics in the 2nd quarter valued at about $104,525,000. Finally, Jupiter Topco LLC acquired a new position in Maze Therapeutics in the 2nd quarter valued at about $101,764,000.
Wall Street Analyst Weigh In
A number of research analysts recently weighed in on MAZE shares. TD Cowen raised shares of Maze Therapeutics to a “strong-buy” rating in a research note on Monday, August 24th. BTIG Research restated a “buy” rating and issued a $46.00 target price on shares of Maze Therapeutics in a research report on Wednesday, August 12th. Wall Street Zen cut Maze Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Maze Therapeutics in a report on Wednesday, June 24th. Three investment analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $66.00.
Get Our Latest Stock Report on MAZE
About Maze Therapeutics
Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.
Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.
Read More
- Five stocks we like better than Maze Therapeutics
- AeroVironment’s Record Backlog and Earnings Beat Fuel Recovery Case
- Corning Just Locked In a Massive Verizon Fiber Deal as AI Infrastructure Expands
- 3 Under-$20 Stocks Tied to the Future of U.S. Energy and Materials
- Uncle Sam’s Quantum Leap: Feds Fund a $300M Quantum Supercycle
Receive News & Ratings for Maze Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maze Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
